Navigation Links
Results From Pilot Trial of PLC's RenalGuard® Published in International Journal of Cardiology
Date:1/17/2012

MILFORD, Mass., Jan. 17, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, today announced that an article summarizing the results from its U.S. pilot trial for RenalGuard® has been published online in the December 26, 2011 International Journal of Cardiology, a peer-reviewed journal affiliated with the International Society of Adult Congenital Heart Disease. The results from this trial, which was completed in 2007 and presented at the American College of Cardiology conference in March 2009, confirmed that RenalGuard System™ "is safe and dynamically balances volume hydration."   

The trial was conducted in four clinical sites in the U.S. in 2006 and 2007, with a total of 23 patients enrolled, and was designed to evaluate the safety of RenalGuard System and RenalGuard Therapy®, under an Investigational Device Exemption (IDE) approved by the U.S. Food and Drug Administration (FDA).  The results of this feasibility study illustrate that RenalGuard can safely help maintain high rates of urine output without significant hemodynamic or systemic adverse reactions.   

PLC's U.S. pivotal trial to study the efficacy of RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy (CIN) is currently underway under the supervision of Principal Investigators Charles Davidson, MD, Professor of Medicine, Northwestern University Medical School, Richard J. Solomon, MD, Professor of Medicine, University of Vermont College of Medicine and Roxana Mehran, MD, Professor of Medicine at Mount Sinai School of Medicine.

The International Journal of Cardiology article can be accessed at the following link: 

SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , , ... Orphan Drug Designation , SILVER SPRING, Md., Dec. 23 ... more transparent and accessible, the FDA has scheduled a series of ... unfamiliar with the process. The FDA can grant a special status, ...
... , , PHILADELPHIA, Dec. 23 URL Pharma today announced ... initiative designed to save patients money on their health insurance co-payment ... no more than $25 for a Colcrys prescription, which equates to ... the prevention and treatment of gout flares and for the treatment ...
Cached Medicine Technology:FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 3URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 4
(Date:7/10/2014)... (July 10, 2014) Men who experience hot flashes ... may find relief from their silent suffering if ... to findings from a Baylor University case study., After ... who had uncontrolled hot flashes following prostate cancer surgery ... but also an impressive improvement in sleep quality, according ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... MADISON, Wis., and BIRMINGHAM, Ala., Sept. 14 ... is now offering a specialized,professional liability program ... being made available through Physicians Insurance Company,of ... "We are pleased to have the ...
... (HealthDay News) -- It,s under your movie seat and glued ... relief may be in sight. This week, researchers say they,ll ... at the BA Festival of Science in York, England. , ... and sidewalks, and preliminary tests indicate that it degrades naturally ...
... STAUNTON, Va., Sept. 14 Michael Bond has,been ... joins,the company following nearly 30 years in various ... Director of Blade Process,Engineering. Bond has a wealth ... advancement of leading edge technologies for,IncisionTech and Specialty ...
... Sept. 14 Stryker,Corporation (NYSE: SYK ) announced ... September 25, 2007 - 4:30 p.m. Eastern Time ... New York A simultaneous webcast of the Company,s ... via the For Investors page. The,presentation for the ...
... Sept. 14 Most people looking for tax advice,usually ... usually see,mechanics, right? Here,s more on a new report ... and questions are actually not seeing the pros,trained in ... at:, http://media.medialink.com/WebNR.aspx?story=33829 Registered journalists can access video, ...
... Mylan Laboratories Inc.,(NYSE: MYL ) today announced ... of Senior Vice President and Chief Compliance Officer. ... where she was,Director of Compliance for Latin America, ... for all compliance-related matters in those,regions. Prior to ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2
... Flexible Cystoscope System using EndoSheath Technology ... for urologists in both their hospitals ... CST-2000 flexible cystoscope with the sterile, ... cystoscopy procedures, while minimizing the costs ...
... Super-Sect is a single-use device that ... minimal thermal spread and vapor sealing ... It can be used for resection ... tumor. It is also an excellent ...
... Cryocare® CS is a ... and treatment system designed ... allow unlimited flexibility. Cryocare ... meet specific physician needs ...
... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
Medicine Products: